Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Operations (QoQ)Cash from Operations Growth (1y)EBIT (QoQ)EBIT Growth (1y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBT (QoQ)EBT Growth (1y)EBT Margin (QoQ)EBT Margin Growth (1y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)Enterprise Value (QoQ)Enterprise Value Growth (1y)FCF Margin (QoQ)FCF Margin Growth (1y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Income (QoQ)Net Income Growth (1y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Margin (QoQ)Net Margin Growth (1y)Operating Income (QoQ)Operating Income Growth (1y)Operating Margin (QoQ)Operating Margin Growth (1y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Return on Assets (QoQ)Return on Assets Growth (1y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Equity (QoQ)Return on Equity Growth (1y)Return on Invested Capital (QoQ)Return on Invested Capital Growth (1y)Return on Sales (QoQ)Return on Sales Growth (1y)Revenue (QoQ)Revenue Growth (1y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Tax Rate (QoQ)Tax Rate Growth (1y)
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Monte Rosa Therapeutics (GLUE) Other Accumulated Expenses: 2023-2025
Generated on {Timestamp}
© BusinessQuant.com
Generated on {Timestamp}
Powered by 
Peer Comparison
Historic Data
Download Data 🔒| Date | Value |
|---|---|